BioDelivery Sciences International Company Profile (NASDAQ:BDSI)

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International logoBioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:BDSI
  • CUSIP: 09060J10
  • Web: www.bdsi.com
Capitalization:
  • Market Cap: $130.01 million
  • Outstanding Shares: 55,325,000
Average Prices:
  • 50 Day Moving Avg: $1.82
  • 200 Day Moving Avg: $1.88
  • 52 Week Range: $1.50 - $3.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.62
  • P/E Growth: 1.530
Sales & Book Value:
  • Annual Revenue: $40.85 million
  • Price / Sales: 3.18
  • Book Value: $0.69 per share
  • Price / Book: 3.41
Profitability:
  • EBIDTA: ($35,530,000.00)
  • Net Margins: -93.61%
  • Return on Equity: -309.49%
  • Return on Assets: -48.76%
Debt:
  • Debt-to-Equity Ratio: -3.47%
  • Current Ratio: 1.74%
  • Quick Ratio: 1.62%
Misc:
  • Average Volume: 594,183 shs.
  • Beta: 1.02
  • Short Ratio: 10.62
 

Frequently Asked Questions for BioDelivery Sciences International (NASDAQ:BDSI)

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) posted its quarterly earnings results on Monday, May, 15th. The company reported $0.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.09 by $0.49. The firm had revenue of $29.48 million for the quarter, compared to analyst estimates of $27.07 million. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. View BioDelivery Sciences International's Earnings History.

Where is BioDelivery Sciences International's stock going? Where will BioDelivery Sciences International's stock price be in 2017?

6 analysts have issued 12 month price objectives for BioDelivery Sciences International's stock. Their predictions range from $3.00 to $5.00. On average, they anticipate BioDelivery Sciences International's share price to reach $4.00 in the next twelve months. View Analyst Ratings for BioDelivery Sciences International.

What are analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:

  • 1. Cantor Fitzgerald analysts commented, "A Lot of Moving Parts and 1x Items: BDSI reported 1Q17 results posting net income of $0.89, the majority of which was attributed to positive effects of the Belbuca return. These items included $20M in deferred revenue recognition, $27M in non-cash bargain purchase gain and a $16M tax benefit. Without these additions, BDSI would have reported a loss of ($0.23). BDSI finished 1Q with $35.2M in cash, which the company estimates should fund operations into 2H18. We have adjusted our estimates to reflect quarter and year end results. Alignment of Fundamentals: We have watched the re-launch of Belbuca closely following the ENDP transition with the recently expanded sales force growing Rx numbers through 1Q and April, per Symphony data. More importantly, $/Rx continues to increase with due to larger prescriptions and incremental price increases. We also note a significant shift to commercial payor which should allow for increased gross/net adding to the top-line. The expanded sales force of 65 armed with revised marketing messaging, particularly around titration, has been targeting physicians familiar with the buprenorphine molecule with success, in our view. We believe additional education campaigns such as speaker programs and a PAINWeekEND symposium will drive interest. Additional Upside: We see additional upside as BDSI focuses on managed Medicaid contracts of which BDSI as of Feb." (5/16/2017)
  • 2. FBR & Co analysts commented, "BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18." (3/20/2017)
  • 3. According to Zacks Investment Research, "BioDelivery expects Bunavail to benefit from the Health and Human Services (HHS) ruling and new contract wins. However, Belbuca’s start has been slower than expected due to pain market pressures. Moreover, the company discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates target highly genericized, crowded and competitive markets. Its share price also underperformed Zacks classified Medical-Biomed/Genetics Market in last one year. On the flip side, since this July, the company has secured improved positioning in six new managed care contracts, providing preferred access to Bunavail, which is expected to boost the drug’s sales and profitability in 2017. Estimates have been going down lately ahead of the company’s Q4 earnings release. The company has mixed record of earnings surprises in recent quarters." (3/14/2017)

Who are some of BioDelivery Sciences International's key competitors?

Who owns BioDelivery Sciences International stock?

BioDelivery Sciences International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (9.85%), Stonepine Capital Management LLC (5.19%), Ameriprise Financial Inc. (4.33%), Vanguard Group Inc. (4.15%), Grandeur Peak Global Advisors LLC (1.84%) and Bank of Montreal Can (1.32%). Company insiders that own BioDelivery Sciences International stock include Barry I Feinberg, Charles Bramlage, Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr, Thomas D'alonzo and William B Stone. View Institutional Ownership Trends for BioDelivery Sciences International.

Who sold BioDelivery Sciences International stock? Who is selling BioDelivery Sciences International stock?

BioDelivery Sciences International's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Morgan Stanley, Searle & CO., Sabby Management LLC, Janney Montgomery Scott LLC, Bank of Montreal Can and California Public Employees Retirement System. Company insiders that have sold BioDelivery Sciences International stock in the last year include Francis E Odonnell Jr, Mark A Sirgo, Niraj Vasisht, Paolantonio Ernest Robert De, Samuel P Sears, Jr and William B Stone. View Insider Buying and Selling for BioDelivery Sciences International.

Who bought BioDelivery Sciences International stock? Who is buying BioDelivery Sciences International stock?

BioDelivery Sciences International's stock was bought by a variety of institutional investors in the last quarter, including Hikari Power Ltd, Stonepine Capital Management LLC, Blair William & Co. IL, Renaissance Technologies LLC, KCG Holdings Inc., Grandeur Peak Global Advisors LLC, Vanguard Group Inc. and Geode Capital Management LLC. Company insiders that have bought BioDelivery Sciences International stock in the last two years include Barry I Feinberg, Charles Bramlage, Niraj Vasisht, Paolantonio Ernest Robert De and Thomas D'alonzo. View Insider Buying and Selling for BioDelivery Sciences International.

How do I buy BioDelivery Sciences International stock?

Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BioDelivery Sciences International stock cost?

One share of BioDelivery Sciences International stock can currently be purchased for approximately $2.35.

Analyst Ratings

Consensus Ratings for BioDelivery Sciences International (NASDAQ:BDSI) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $4.00 (70.21% upside)

Analysts' Ratings History for BioDelivery Sciences International (NASDAQ:BDSI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017ValuEngineUpgradeSell -> HoldLowView Rating Details
5/16/2017Roth CapitalSet Price TargetBuy$5.00MediumView Rating Details
5/16/2017FBR & CoSet Price TargetBuy$4.00MediumView Rating Details
5/16/2017Cantor FitzgeraldUpgradeNeutral -> Overweight$3.00 -> $4.00LowView Rating Details
3/20/2017Janney Montgomery ScottReiterated RatingBuy$3.00HighView Rating Details
8/10/2016Piper Jaffray CompaniesReiterated RatingSell$4.00N/AView Rating Details
3/14/2016LaidlawLower Price TargetBuy$17.00 -> $11.00N/AView Rating Details
9/18/2015William BlairReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)
Earnings by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Earnings History by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017$0.09$0.58$27.07 million$29.48 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.26)($0.29)$6.37 million$3.90 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.30)$3.58 million$3.60 millionViewListenView Earnings Details
8/9/2016Q216($0.31)($0.31)$3.35 million$5.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.35)($0.36)$2.96 million$3.00 millionViewListenView Earnings Details
3/10/2016Q415$0.55$0.19$52.40 million$32.20 millionViewListenView Earnings Details
11/9/2015Q315($0.34)($0.39)$1.56 million$1.20 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.37)$3.29 million$1.70 millionViewListenView Earnings Details
5/11/2015Q115($0.20)($0.16)$10.80 million$13.10 millionViewListenView Earnings Details
3/16/2015Q414($0.40)($0.51)$4.00 million$2.50 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.29)($0.39)$3.02 million$1.82 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.07)($0.14)$11.65 million$13.89 millionViewN/AView Earnings Details
5/9/2014Q114($0.15)($0.11)$11.60 million$20.69 millionViewN/AView Earnings Details
3/14/2014($0.22)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for BioDelivery Sciences International (NASDAQ:BDSI)
2017 EPS Consensus Estimate: ($0.87)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.22)$0.09($0.10)
Q2 20173($0.31)($0.20)($0.25)
Q3 20173($0.30)($0.23)($0.26)
Q4 20173($0.29)($0.21)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BioDelivery Sciences International (NASDAQ:BDSI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for BioDelivery Sciences International (NASDAQ:BDSI)
Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 53.57%
Insider Trades by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Insider Trades by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/31/2017Mark A SirgoCEOSell110,895$1.90$210,700.50View SEC Filing  
3/23/2017Francis E Odonnell JrDirectorSell750$1.90$1,425.00View SEC Filing  
3/23/2017Niraj VasishtSVPSell530$1.90$1,007.00View SEC Filing  
3/23/2017Paolantonio Ernest Robert DeCFOSell170$1.90$323.00View SEC Filing  
1/30/2017Niraj VasishtInsiderSell6,905$1.91$13,188.55View SEC Filing  
12/1/2016Samuel P. Sears, Jr.DirectorSell12,000$1.67$20,040.00View SEC Filing  
11/23/2016Barry I FeinbergDirectorBuy2,000$1.67$3,340.00View SEC Filing  
11/17/2016Barry I FeinbergDirectorBuy3,000$1.87$5,610.00View SEC Filing  
9/23/2016Francis E Odonnell JrDirectorSell100,000$2.57$257,000.00View SEC Filing  
9/23/2016Niraj VasishtInsiderSell47,000$2.43$114,210.00View SEC Filing  
9/22/2016Paolantonio Ernest Robert DeCFOSell14,800$2.44$36,112.00View SEC Filing  
8/25/2016Barry I FeinbergDirectorBuy2,500$2.55$6,375.00View SEC Filing  
8/11/2016William B StoneDirectorSell16,000$2.57$41,120.00View SEC Filing  
3/21/2016Charles BramlageDirectorBuy8,850$2.82$24,957.00View SEC Filing  
3/18/2016Barry I FeinbergDirectorBuy10,000$2.74$27,400.00View SEC Filing  
3/18/2016Niraj VasishtCTOBuy1,000$2.80$2,800.00View SEC Filing  
3/17/2016Paolantonio Ernest Robert DeCFOBuy4,000$2.60$10,400.00View SEC Filing  
11/24/2015Francis E Odonnell JrDirectorSell50,000$6.01$300,500.00View SEC Filing  
11/13/2015Thomas D'alonzoDirectorBuy4,528$5.52$24,994.56View SEC Filing  
9/3/2015Francis E Odonnell JrDirectorSell20,000$6.43$128,600.00View SEC Filing  
8/26/2015Paolantonio Ernest Robert DeCFOBuy1,650$6.20$10,230.00View SEC Filing  
8/13/2015William B StoneDirectorSell11,500$7.01$80,615.00View SEC Filing  
6/16/2015Francis E Odonnell JrDirectorSell21,597$8.03$173,423.91View SEC Filing  
6/16/2015Mark A SirgoCEOSell4,187$7.97$33,370.39View SEC Filing  
5/26/2015Barry I FeinbergDirectorBuy2,000$7.84$15,680.00View SEC Filing  
5/14/2015Barry I FeinbergDirectorBuy2,000$8.54$17,080.00View SEC Filing  
5/13/2015Thomas D'alonzoDirectorBuy6,226$8.07$50,243.82View SEC Filing  
12/26/2014Francis E Odonnell JrDirectorSell70,000$12.00$840,000.00View SEC Filing  
12/15/2014Mark A SirgoCEOBuy2,500$12.23$30,575.00View SEC Filing  
12/10/2014Samuel P Sears JrDirectorSell7,853$15.03$118,030.59View SEC Filing  
11/12/2014William B StoneDirectorSell14,000$16.11$225,540.00View SEC Filing  
9/4/2014Barry I FeinbergDirectorBuy1,000$15.18$15,180.00View SEC Filing  
9/4/2014Mark A SirgoCEOBuy2,000$15.04$30,080.00View SEC Filing  
8/27/2014Andrew L FinnEVPSell90,000$15.00$1,350,000.00View SEC Filing  
8/22/2014Charles BramlageDirectorBuy1,800$13.85$24,930.00View SEC Filing  
6/25/2014Paolantonio Ernest Robert DeCFOBuy1,250$12.13$15,162.50View SEC Filing  
6/12/2014Samuel P Sears JrDirectorSell5,000$12.33$61,650.00View SEC Filing  
6/11/2014Francis E Odonnell JrDirectorSell125,000$11.04$1,380,000.00View SEC Filing  
3/26/2014Francis Odonnell, Jr.DirectorSell50,000$8.04$402,000.00View SEC Filing  
3/20/2014Samuel Sears, Jr.DirectorSell4,000$9.00$36,000.00View SEC Filing  
3/11/2014Andrew FinnEVPSell80,000$9.99$799,200.00View SEC Filing  
3/11/2014William StoneDirectorSell35,000$10.00$350,000.00View SEC Filing  
2/20/2014Andrew FinnEVPSell18,737$8.84$165,635.08View SEC Filing  
2/20/2014Francis Odonnell, Jr.DirectorSell70,000$8.92$624,400.00View SEC Filing  
2/20/2014Mark SirgoCEOSell42,000$8.92$374,640.00View SEC Filing  
1/24/2014Andrew FinnEVPSell143,679$9.03$1,297,421.37View SEC Filing  
1/24/2014James McnultySVPSell89,223$8.73$778,916.79View SEC Filing  
1/24/2014John SheaDirectorSell130,000$8.78$1,141,400.00View SEC Filing  
1/24/2014Mark SirgoCEOSell116,253$9.01$1,047,439.53View SEC Filing  
11/18/2013Mark SirgoCEOBuy2,337$4.29$10,025.73View SEC Filing  
9/19/2013Francis Odonnell, Jr.DirectorSell95,000$5.36$509,200.00View SEC Filing  
9/11/2013Samuel P Sears JrDirectorSell2,000$5.37$10,740.00View SEC Filing  
9/9/2013Samuel P Sears JrDirectorSell7,500$5.05$37,875.00View SEC Filing  
8/26/2013Andrew FinnEVPBuy5,000$4.58$22,900.00View SEC Filing  
8/16/2013Mark SirgoCEOBuy5,100$4.43$22,593.00View SEC Filing  
8/15/2013William StoneDirectorSell6,825$4.44$30,303.00View SEC Filing  
8/14/2013James McnultyCFOBuy5,000$4.50$22,500.00View SEC Filing  
6/21/2013Mark A SirgoCEOBuy3,400$4.30$14,620.00View SEC Filing  
6/20/2013Francis E Odonnell JrDirectorSell72,689$4.36$316,924.04View SEC Filing  
6/5/2013Samuel P Sears JrDirectorSell5,000$4.42$22,100.00View SEC Filing  
12/21/2012Andrew L FinnEVPBuy3,000$3.85$11,550.00View SEC Filing  
12/21/2012Mark A SirgoCEOBuy4,975$4.02$19,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for BioDelivery Sciences International (NASDAQ:BDSI)
Latest Headlines for BioDelivery Sciences International (NASDAQ:BDSI)
Source:
DateHeadline
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 19 at 4:04 PM
nasdaq.com logoBioDelivery Sciences International (BDSI) Jumps: Stock Up 5% - Nasdaq
www.nasdaq.com - May 19 at 3:48 PM
finance.yahoo.com logoBioDelivery Sciences International (BDSI) Jumps: Stock Up 5%
finance.yahoo.com - May 18 at 11:48 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for BioDelivery Sciences International, Inc. (BDSI) Issued By William Blair
www.americanbankingnews.com - May 18 at 8:20 AM
americanbankingnews.com logoQ2 2017 Earnings Forecast for BioDelivery Sciences International, Inc. (BDSI) Issued By FBR & Co
www.americanbankingnews.com - May 18 at 8:20 AM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Given a $5.00 Price Target at Roth Capital
www.americanbankingnews.com - May 17 at 7:10 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) PT Set at $4.00 by FBR & Co
www.americanbankingnews.com - May 17 at 7:10 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Upgraded to "Overweight" at Cantor Fitzgerald
www.americanbankingnews.com - May 16 at 5:48 PM
finance.yahoo.com logoBDSI CEO on Belbuca revenue potential: We're on an upward trend
finance.yahoo.com - May 16 at 3:57 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Issues Earnings Results
www.americanbankingnews.com - May 16 at 3:24 PM
reuters.com logoBRIEF-Biodelivery Sciences Q1 earnings per share $0.87
www.reuters.com - May 16 at 12:19 PM
seekingalpha.com logoBioDelivery Sciences International, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 16 at 12:19 PM
finance.yahoo.com logoBioDelivery tops Street 1Q forecasts
finance.yahoo.com - May 16 at 12:19 PM
finance.yahoo.com logoEdited Transcript of BDSI earnings conference call or presentation 15-May-17 8:30pm GMT
finance.yahoo.com - May 16 at 12:19 PM
finance.yahoo.com logoBioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains
finance.yahoo.com - May 16 at 12:19 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 16 at 8:40 AM
finance.yahoo.com logoInvestor Network: BioDelivery Sciences International, Inc. to Host Earnings Call
finance.yahoo.com - May 15 at 4:20 PM
finance.yahoo.com logoBioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 15 at 4:20 PM
nasdaq.com logoEarnings Reaction History: BioDelivery Sciences International Inc, 25.0% Follow-Through Indicator, 4.7% Sensitive
www.nasdaq.com - May 15 at 9:04 AM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Expected to Announce Quarterly Sales of $27.07 Million
www.americanbankingnews.com - May 12 at 5:14 PM
seekingalpha.com logoBioDelivery Sciences: ~$2 Biopharma Stock On The Cusp Of A ... - Seeking Alpha
seekingalpha.com - May 11 at 4:25 PM
prnewswire.com logoBioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday ... - PR Newswire (press release)
www.prnewswire.com - May 11 at 4:25 PM
reuters.com logoBRIEF-Biodelivery Sciences International files for non-timely 10-Q - SEC Filing
www.reuters.com - May 11 at 2:09 AM
americanbankingnews.com logo Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Post Earnings of $0.09 Per Share
www.americanbankingnews.com - May 10 at 8:18 AM
finance.yahoo.com logoBioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday, May 15
finance.yahoo.com - May 9 at 3:54 PM
zacks.com logoWhat's in Store for BioDelivery (BDSI) this Earnings Season?
www.zacks.com - May 8 at 3:46 PM
finance.yahoo.com logoWhat's in Store for BioDelivery (BDSI) this Earnings Season?
finance.yahoo.com - May 8 at 10:34 AM
seekingalpha.com logoBioDelivery Sciences: Belbuca Transition Appears To Have Worked - Seeking Alpha
seekingalpha.com - May 7 at 4:05 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 1:01 AM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 6 at 12:42 AM
finance.yahoo.com logoBioDelivery Sciences Announces the Approval of BUNAVAIL® for ... - Yahoo Finance
finance.yahoo.com - May 4 at 9:00 PM
streetinsider.com logoBioDelivery Sciences (BDSI) Announces FDA Approval of BUNAVAIL for Induction of Buprenorphine Treatment for ... - StreetInsider.com
www.streetinsider.com - May 4 at 4:00 PM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) Getting Favorable News Coverage, Report Finds
www.americanbankingnews.com - May 3 at 1:21 PM
finance.yahoo.com logoBDSI's expanded approval of opioid dependence drug required few resources, exec says
finance.yahoo.com - May 3 at 12:47 PM
finance.yahoo.com logoBioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment for Opioid Dependence
finance.yahoo.com - May 2 at 11:17 AM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) Earns Daily Media Impact Rating of 0.06
www.americanbankingnews.com - April 30 at 1:34 PM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) Earns Daily Media Sentiment Rating of 0.06
www.americanbankingnews.com - April 26 at 7:02 PM
finance.yahoo.com logoBioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 26 at 11:49 AM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) Receives Daily Coverage Optimism Score of 0.17
www.americanbankingnews.com - April 21 at 12:03 PM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 21 at 11:57 AM
americanbankingnews.com logo Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Post Earnings of $0.09 Per Share
www.americanbankingnews.com - April 19 at 7:34 AM
americanbankingnews.com logoPositive Media Coverage Somewhat Likely to Affect BioDelivery Sciences International (BDSI) Stock Price
www.americanbankingnews.com - April 18 at 1:02 PM
finance.yahoo.com logoBioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 18 at 12:16 PM
americanbankingnews.com logoShort Interest in BioDelivery Sciences International, Inc. (BDSI) Decreases By 2.6%
www.americanbankingnews.com - April 17 at 12:10 PM
americanbankingnews.com logoBioDelivery Sciences International (BDSI) Getting Somewhat Negative Media Coverage, Report Shows
www.americanbankingnews.com - April 15 at 10:29 AM
americanbankingnews.com logoBioDelivery Sciences International, Inc. (BDSI) Given a $5.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - April 9 at 11:28 PM
finance.yahoo.com logoNew cash, patents boost optimism at Raleigh's BioDelivery Sciences
finance.yahoo.com - April 7 at 8:25 AM
streetinsider.com logoPre-Open Movers 03/31: (SORL) (BBRY) (BDSI) Higher; (DRIO) (BLRX) (CTSO) Lower (more...)
www.streetinsider.com - March 31 at 4:00 PM
reuters.com logoBRIEF-Biodelivery Sciences announces the granting of two new patents
www.reuters.com - March 31 at 4:00 PM
investopedia.com logoBioDelivery Sciences Secures Two Patents (BDSI)
www.investopedia.com - March 31 at 4:00 PM

Social

BioDelivery Sciences International (BDSI) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff